Cabozantinib prolongs progression-free survival in patients with previously treated radioiodine-refractory differentiated thyroid cancer, a phase 3 trial suggests.
All articles by Leah Lawrence
Nearly 70% of patients had at least 1 potentially actionable therapeutic target.
The test can accurately detect cancer and predict where it is located, according to researchers.
Patients with parathyroid carcinoma after localized resection for a presumed benign indication should undergo close monitoring for recurrence rather than radical surgery.
Cabozantinib significantly improved progression-free survival, and there was a trend toward improved overall survival.